A shortage of a versatile medicine used to treat immune disorders has forced US hospitals to stop treatment for many patients.
Hospitals have begun rationing the immunoglobulin drugs (IG), prioritising patients that are most at risk of death if they go without.
IG is used to treat immune disorders such as lupus, myositis and Guillain-Barre syndrome.
Few AIM-listed drug development companies have late-stage clinical assets in the pipeline, ImmuPharma plc (LON:IMM) is an exception. The Company’s lead compound, Lupuzor™, a potential treatment for Lupus, has completed Phase 3 trial of dosing patients across the US, Europe and Mauritius with top line results announced.